2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2066

Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Abstract Number: 2796

Elevated Serum Immunoglobulin G Is a Prognostic Factor for Progression of Interstitial Lung Disease in Primary Sjögren’s Syndrome
Abstract Number: 821

Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis
Abstract Number: 2721

Elevated Subgingival Levels of Periodontal Pathogens in Rheumatoid Arthritis Patients, Particularly Leptotrichia species in New-Onset Disease
Abstract Number: 1526

Employment and Quality of Life Among Patients with Rheumatoid Arhtritis in Four Latin-American Countries
Abstract Number: 1570

End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis
Abstract Number: 3141

Endothelial Cells Regulate Proinflammatory T Cell Responses in Large Vessel Vasculitis Via NOTCH-NOTCH Ligand Interactions
Abstract Number: 2934

Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Abstract Number: 3014

Endotrophin: A Novel Adipokine Linking Adipose Tissue and Skin Fibrosis in Systemic Sclerosis
Abstract Number: 1498

Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology
Abstract Number: 2221

Engaging Learners in Lupus Education with Pivot (Practice Improvement using Virtual Online Training), a Novel, Digital Case-Based Curriculum
Abstract Number: 1938

Engaging PD-1 Resuscitates Synovial Treg Cells and Dampens the Joint Infiltrating T Cells in Rheumatoid Arthritis
Abstract Number: 2829

Enhanced Expression of the Transcription Factor T-Bet Alters Pro-Inflammatory Cytokine Profile in Ankylosing Spondylitis
Abstract Number: 1369

Enhanced Myelopoiesis Downstream of Toll-like Receptor 9 Activation Drives a Feed-Forward Inflammatory Response
Abstract Number: 1605

Enhanced Oxidant Signaling in Inflammatory Macrophages in Rheumatoid Arthritis (RA) and in Coronary Artery Disease (CAD)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].